Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EFFECTOR THERAPEUTICS, INC.

(EFTR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
19.28(c) 18.89(c) 18.65(c) 17.15(c) 16.89 Last
1 058 749 275 956 466 031 589 914 506 084 Volume
+7.95% -2.02% -1.27% -8.04% -1.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,47 M - -
Net income 2021 -32,9 M - -
Net cash position 2021 37,0 M - -
P/E ratio 2021 -15,4x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -42,4 M - -
Net cash position 2022 161 M - -
P/E ratio 2022 -18,2x
Yield 2022 -
Capitalization 687 M 687 M -
EV / Sales 2021 1 393x
EV / Sales 2022 -
Nbr of Employees -
Free-Float 67,4%
More Financials
Company
eFFECTOR Therapeutics, Inc., formerly Locust Walk Acquisition Corp, is a clinical-stage biopharmaceutical company. The Company focuses on the development of oncology drugs named selective translation regulator inhibitors (STRIs). It uses selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex... 
Sector
Biotechnology & Medical Research
Calendar
09/28 | 02:40pmPresentation
More about the company
All news about EFFECTOR THERAPEUTICS, INC.
09/21EFFECTOR THERAPEUTICS : JMP Securities Starts eFFECTOR Therapeutics at Market Outperform w..
MT
09/20EFFECTOR THERAPEUTICS : Stifel Starts eFFECTOR Therapeutics at Hold with $20 Price Target
MT
09/16EFFECTOR THERAPEUTICS : to Participate in 2021 Cantor Virtual Healthcare Conference
AQ
09/13EFFECTOR THERAPEUTICS : Cantor Fitzgerald Starts eFFECTOR Therapeutics at Overweight With ..
MT
09/08EFFECTOR THERAPEUTICS : Shares Soar Amid Heavy Trading Volume
MT
08/31EFFECTOR THERAPEUTICS : Changes in Registrant's Certifying Accountant, Amendments to Artic..
AQ
08/31LOCT WALK : Unaudited condensed financial information of Old eFFECTOR as of and for the th..
PU
08/31EFFECTOR THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets (form 8-K..
AQ
08/30Top Premarket Decliners
MT
08/25SECTOR UPDATE : Health Care Stocks Largely Down This Afternoon
MT
08/25Top Midday Gainers
MT
08/25LOCUST WALK ACQUISITION : Shares Surge After Shareholders Approve Pending Merger With eFFE..
MT
08/25Wall Street in Holding Pattern, Stabilizing in Run-Up to Jackson Hole
MT
08/25US Futures Stabilize in Jackson Hole Run-Up
MT
08/25Top Premarket Gainers
MT
More news
News in other languages on EFFECTOR THERAPEUTICS, INC.
09/08Les actions d'Effector Therapeutics s'envolent dans un volume d'échanges important
More news
Analyst Recommendations on EFFECTOR THERAPEUTICS, INC.
More recommendations
Chart EFFECTOR THERAPEUTICS, INC.
Duration : Period :
eFFECTOR Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EFFECTOR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 16,89 $
Average target price 34,33 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Stephen T. Worland President, Chief Executive Officer & Director
Michael Byrnes Chief Financial Officer & Secretary
Brian M. Gallagher Chairman
Premal Patel Chief Medical Officer
Larry Lasky Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EFFECTOR THERAPEUTICS, INC.0.00%697
GILEAD SCIENCES, INC.20.85%89 259
BIONTECH SE276.71%80 542
REGENERON PHARMACEUTICALS28.14%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.40%47 634